TuHURA Secures U.S. Patent for Delta Opioid Receptor Technology, Expanding Immunotherapy Applications

  • TuHURA Biosciences received U.S. Patent No. 12,734,168 for its Delta Opioid Receptor (DOR) antagonist technology, issued on September 15, 2026.
  • The patent covers applications beyond ADCs, including CAR-T, Treg, and TIL cellular therapies.
  • TuHURA's DOR technology targets Myeloid-Derived Suppressor Cells (MDSCs) to enhance cancer immunotherapy effectiveness.
  • The patent term extends through 2043, providing long-term intellectual property protection.

TuHURA's patent strengthens its position in overcoming resistance to cancer immunotherapy, a critical challenge in the field. The broad applicability of its DOR technology to various immunotherapy classes could position the company as a key player in addressing T cell exhaustion and acquired resistance. The long patent term provides a strategic advantage in a sector where intellectual property is crucial for competitive differentiation.

Clinical Progress
How TuHURA's preclinical models for blood-related cancers like AML and MDS will validate its DOR technology.
Market Positioning
Whether TuHURA can leverage this patent to differentiate itself in the competitive immuno-oncology space.
Regulatory Pathway
The pace at which TuHURA advances its DOR technology through clinical trials and potential regulatory approvals.